ERBB2 and breast cancer: HER2 targeted therapies trastuzumab and pertuzumab in combination with chemotherapy in the neoadjuvant setting is effective in a subset of patients with HER2pos BC, but in parallel hematologic and non-hematologic toxicities have been frequently noted in a substantial fraction of patients.13 14 This suggests that an alternate combination treatment approach is needed to enhance the clinical response and overcome chemotherapy induced toxicities in patients with HER2pos BC.